ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis and Akzo grow R&D in China

by Jean-François Tremblay
June 6, 2016 | APPEARED IN VOLUME 94, ISSUE 23

Novartis has inaugurated new R&D buildings and labs in Shanghai. The expansion of the Novartis Institutes for BioMedical Research in Shanghai will provide space for as many as 1,300 scientists, up from 500 previously. Research at the center focuses on infections that lead to cancer in Asian patients. In addition, scientists at the center perform discovery chemistry and biomarker research. Separately, AkzoNobel opened its largest R&D center in China, also in Shanghai. The Dutch firm invested more than $7 million in the facility, which employs 150 scientists focusing on coatings and specialty chemicals.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment